These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19673349)

  • 1. [Antimicrobial susceptibility surveillance of recent isolates from otorhinolaryngological infections to garenoxacin and other antimicrobial drugs].
    Suzuki K; Kurono Y; Kobayashi T; Nishimura T; Baba S; Harabuchi Y; Fujisawa T; Yamanaka N; Ubukata K; Ikeda F
    Jpn J Antibiot; 2009 Apr; 62(2):71-8. PubMed ID: 19673349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro activity of sitafloxacin against clinical isolates in 2012].
    Amano A; Matsuzaki K; Kishi N; Koyama H; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Okutani Y
    Jpn J Antibiot; 2013 Dec; 66(6):311-30. PubMed ID: 24649797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
    Suzuki K; Kurono Y; Kobayashi T; Nishimura T; Baba S; Harabuchi Y; Fujisawa T; Yamanaka N; Ubukata K; Ikeda F
    Jpn J Antibiot; 2010 Aug; 63(4):312-8. PubMed ID: 21298864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of sitafloxacin against clinical isolates in 2009].
    Amano A; Matsuzaki K; Kishi N; Saika T; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Kanda Y; Shiozawa T
    Jpn J Antibiot; 2010 Dec; 63(6):411-30. PubMed ID: 21425595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
    Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Activities of antimicrobial agents against 8,474 clinical isolates obtained from 37 medical institutions during 2000 in Japan].
    Yamaguchi K; Ohno A; Kashitani F; Iwata M; Kanda M; Tsujio Y; Sugiyama T; Toyoshima S; Kato J; Watanabe N; Kaku M; Kanemitsu K; Kunishima H; Kawaguchi H; Okada J; Shimoyama N; Igari J; Oguri T; Kaimori M; Watanabe K; Kobayashi Y; Uchida H; Katayama Y; Sugimoto K; Tashiro H; Kanno H; Yasujima M; Itoh K; Suwabe A; Obata R; Okada M; Kobayashi S; Tsuzimura M; Itoh A; Sumitomo M; Taminato T; Negayama K; Baba H; Makino H; Murase M; Miyamoto H; Minakuchi K; Ishigo S; Takii M; Horii T; Ono J; Takata T; Yamanaka K; Hamazaki N; Tsutsui T; Okabe H; Tatewaki K; Moro K; Hiramatsu K; Saikawa T; Ichiyama S; Nagasawa Z; Aoki Y; Matsushima T; Niki Y; Hirakata Y; Kohno S; Kuwabara M; Nakagawa K; Kageoka T; Hongo T; Yamane N
    Jpn J Antibiot; 2003 Oct; 56(5):341-64. PubMed ID: 14692376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nationwide surveillance of 6 otorhinolaryngological infectious diseases and antimicrobial susceptibility pattern in the isolated pathogens in Japan.
    Suzuki K; Kurono Y; Ikeda K; Watanabe A; Iwamoto A; Totsuka K; Kaku M; Iwata S; Kadota J; Hanaki H
    J Infect Chemother; 2015 Jul; 21(7):483-91. PubMed ID: 26004175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The seventh nationwide surveillance of six otorhinolaryngological infectious diseases and the antimicrobial susceptibility patterns of the isolated pathogens in Japan.
    Suzuki K; Kurono Y; Ikeda K; Hotomi M; Yano H; Watanabe A; Matsumoto T; Takahashi Y; Hanaki H
    J Infect Chemother; 2020 Sep; 26(9):890-899. PubMed ID: 32622623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
    Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
    Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In-vitro susceptibilites to levofloxacin and various antibacterial agents of 18,639 clinical isolates obtained from 77 centers in 2004].
    Yamaguchi K; Ohno A; Ishii Y; Tateda K; Iwata M; Kanda M; Tsujio Y; Kimoto H; Kaimori M; Nakamura T; Kawamura C; Nishimura M; Akizawa K; Katayama Y; Matsuda K; Hayashi T; Yasujima M; Kasai T; Kimura M; Tominaga M; Miki M; Nakanowatari S; Nakagawa T; Kaku M; Kanemitsu K; Kunishima H; Toyoshima S; Sakurai M; Shiotani J; Sugita A; Ito T; Okada J; Suwabe A; Yamahata K; Yoneyama A; Kumasaka K; Yamane N; Koike K; Ieiri T; Kominami H; Yamada T; Oguri T; Itoh K; Watanabe K; Kobayashi Y; Ohtake T; Uchida T; Totsuka K; Murakami M; Yomoda S; Takahashi A; Okamoto H; Inuzuka K; Yamazaki K; Gonda H; Yamashita T; Yamaguchi I; Okada M; Ikari H; Kurosawa N; Fujimoto Y; Ishigo S; Asano Y; Mikio M; Kano I; Nagano E; Kageyama F; Shaku E; Kanno H; Aihara M; Gemma H; Uemura K; Miyajima E; Maesaki S; Hashikita G; Horii T; Sumitomo M; Yoshimura H; Hiraoka M; Wada H; Yuzuki Y; Ikeda N; Baba H; Soma M; Yamamoto T; Ichiyama S; Kinosita S; Kawano S; Fujita S; Kageoka T; Hongo T; Okabe H; Tatewaki K; Moro K; Oka M; Niki Y; Yoshida H; Yamashita M; Kusano N; Mihara E; Nose M; Fushiwaki T; Kuwabara M; Fujiue Y; Shimuzu A; Takubo T; Kusakabe T; Hinoda Y; Tanaka N; Takahashi H; Heijyou H; Okazaki T; Asai K; Kawahara K; Masuda J; Sano R; Taminato T; Negayama K; Matsuo S; Komatsu M; Sugiura T; Murase M; Hiramatsu K; Yamane N; Nakasone I; Hirakata Y; Kohno S; Aizawa H; Honda J; Hamazaki N; Okayama A; Ono J; Aoki Y; Okada K; Miyanohara H
    Jpn J Antibiot; 2006 Dec; 59(6):428-51. PubMed ID: 17334061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antimicrobial susceptibility surveillance of recent isolates from ophthalmological infections to gatifloxacin and other antimicrobial drugs].
    Matsuzaki K; Koyama H; Watabe E; Hasegawa M; Sato Y; Kobayashi I
    Jpn J Antibiot; 2005 Feb; 58(1):45-9. PubMed ID: 15847222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E; Dalhoff A; Korfmann G
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN; Fritsche TR; Sader HS; Stilwell MG
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Susceptibility of clinically-isolated bacteria strains to respiratory quinolones and evaluation of antimicrobial agent efficacy by Monte Carlo simulation].
    Kosaka T; Yamada Y; Kimura T; Kodama M; Fujitomo Y; Masaki N; Toshiaki K; Keisuke S; Fujita N
    Jpn J Antibiot; 2016 Feb; 69(1):27-40. PubMed ID: 27290828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bactericidal activity of sitafloxacin and other new quinolones against antimicrobial resistant Streptococcus pneumoniae].
    Kobayashi I; Kanayama A; Hasegawa M; Kaneko A
    Jpn J Antibiot; 2013 Feb; 66(1):25-35. PubMed ID: 23777014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.